01/08/2009
Doctors urged to get training on immune diseases (AME Info)
The Arab world needs to start educating doctors about immune disorders as early diagnosis can have a huge impact on the outcome, Dr Muhammad Asim Khan, a professor of medicine at Case Western Reserve University in Ohio said yesterday at a meeting of doctors in Dubai.
MORE INFO
|
01/08/2009
Stem cell therapy developed at Imperial College London boosts body's ability to heal itself (Guardian Unlimited)
A groundbreaking medical treatment that could dramatically enhance the body's ability to repair itself has been developed by a team of British researchers. The therapy, which makes the body release a flood of stem cells into the bloodstream, is designed to heal serious tissue damage caused by heart attacks and even repair broken bones. It is expected to enter animal trials later this ...
MORE INFO
|
01/08/2009
Baxter and Northwestern University partner to target new life sciences projects (EurekAlert!)
( Northwestern University ) Northwestern University and Baxter Healthcare Corporation will create a multidisciplinary research and innovation alliance, the two entities announced today. Under the three-year renewable agreement, Baxter will fund research-collaboration projects at Northwestern. Funding levels for each year may reach approximately $1 million, and Baxter will determine specific ...
MORE INFO
|
01/08/2009
Medical devices not immune to recession (Beloit Daily News)
WASHINGTON (AP) - Health care stocks are typically seen as a hedge against financial downturns, but medical device shares declined steeply in 2008 as broader economic worries exacerbated declines linked to product safety concerns.
MORE INFO
|
01/07/2009
Baxter, Halozyme start phase-III trial of Gammagard Liquid for primary immunodeficiency (PharmaBiz)
Baxter International Inc and Halozyme Therapeutics, Inc announced the start of a phase-III clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10 per cent (IGIV), marketed as Kiovig in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID). The purpose of this clinical ...
MORE INFO
|
01/03/2009
Nutritionist to lead free health seminars (The Desert Sun)
A series of free health seminars about menopause, osteoporosis, thyroid gland dysfunctions, andropause, erectile dysfunction and HIV/AIDS and immune disorders will be offered by local nutritionist Jim Harris over the next three months in Palm Springs.
MORE INFO
|
01/06/2009
Baxter International Fourth Quarter 2008 Financial Results Conference Call (PR Newswire via Yahoo! Finance)
Baxter International , will host a quarterly conference call to discuss its fourth quarter 2008 financial results on Thursday, January 22, 2009, at 8:30 a.m. Eastern Time .
MORE INFO
|
01/06/2009
Phase III Trial Begins For GAMMAGARD LIQUID Plus RHuPH20 In Primary Immunodeficiency Patients (Medical News Today)
Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID).
MORE INFO
|
01/06/2009
Cord Blood America Engages Social Media and Starts Conversation Regarding Stem Cells (Marketwire via Yahoo! Finance)
Cord Blood America, Inc., announced today that the Company will begin to engage its clients, prospective clients, shareholders and prospective investors via social media. Cord Blood America is currently on Twitter, Facebook and soon to be available on FriendFeed.
MORE INFO
|
01/05/2009
Baxter to Present at the 27th Annual J.P. Morgan Healthcare Conference (Business Wire via Yahoo! Finance)
DEERFIELD, Ill.----Baxter International Inc. announced today that it will present at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2009 at 11:00 a.m. or 2:00 p.m. .
MORE INFO
|